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Background and purpose: To ﬁnd the relationship between rtPA treatment vs. MMP-9 activity,
MMP-3, and TIMP-1 serum levels related to patients' neurological status during acute
ischaemic stroke (IS).
Material and methods: 35 IS patients were enrolled. 14 of them underwent thrombolytic
therapy with Actylise (rtPA group). The serum samples were obtained at 3 time-points for
rtPA group (time-point 0: 1st–4th hour of stroke; time-point 1 – immediately after rtPA
administration; time-point 2 – on day 5–7 from stroke onset). Remaining patients had venous
blood collection at two time-points: time-point 1 – 5th–10th hour of stroke and time-point 2 –
on day 5–7 of stroke. MMP-9 was analyzed with gelatin zymography, MMP-3 and TIMP-1
serum levels were analyzed with ELISA method. NIHSS improvement ratio (IR) was calcu-
lated as a difference between NIHSS score at the admission and discharge of patient.
Results: The active form of MMP-9 (86 kDa) was not observed in any analyzed samples. Total
MMP-9 activity was signiﬁcantly elevated at time-point 1 in rtPA group in comparison with
non-rtPA group. MMP-3 serum level signiﬁcantly decreased during rtPA administration in
comparison with non-rtPA group and it was restored at time-point 2. MMP-3 negatively
correlated with IR values ( p = 0.06).
Conclusions: Thrombolysis applied for IS treatment increases MMP-9 activity in serum,
however, rtPA does not facilitate the conversion of pro-MMP-9 into the active form. Our
results also suggest the involvement of MMP-3 to the biochemical processes occurring
during acute phase of IS.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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The ischaemic stroke (IS) is one of the leading causes of death
and disability worldwide. In spite of well-developed diagnostic* Corresponding author at: Department of Medical Chemistry, Medical
Tel.: +48 81 535 73 90; fax: +48 81 535 73 61.
E-mail address: kurzepa@onet.pl (J. Kurzepa).
http://dx.doi.org/10.1016/j.pjnns.2014.07.012
0028-3843/# 2014 Polish Neurological Society. Published by Elsevier Utools for rapid detection of cerebral ischaemia the recom-
mended treatment is limited to recombinant tissue plasmino-
gen activator (rtPA) [1]. However, due to restrict qualifying
criteria for thrombolytic therapy it can be applied for a few
percentage among of all ischaemic stroke patients [2]. In University of Lublin, Chodzki 4a, 20-093 Lublin, Poland.
rban & Partner Sp. z o.o. All rights reserved.
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centres in order to limit the appearance of side effects [3]. One
of the serious side effects during thrombolytic therapy is an
intracranial bleeding. This event is developed due to overac-
tivity of anticlotting mechanisms trigged by rtPA [4]. Previous
studies indicated that intracranial bleeding within the
ischaemic focus potentially can occur by high baseline activity
of matrix metalloproteinase(MMP)-9 (gelatinase B) [5,6]. MMP-
9 enzyme belongs to MMPs family, capable to digest proteins
located extracellularly. MMPs are involved in numerous
physiological and pathological processes also during the IS
[7]. The involvement of MMP-9 into the development of
intracranial bleeding is caused by its ability to cleave type IV
collagen – the constituent of basal membrane of endothelium.
This process leads to the blood–brain barrier (BBB) destruction.
In addition, MMP-9 can cleave occludin and claudin, the tight
junctions proteins (TJPs) within the BBB [8].
Animal and clinical studies showed the increase of MMP-9
activity over the course of ﬁrst 24 h of stroke [9]. MMP-9
expression is trigged by cerebral ischaemia and inﬂammatory
process occurring within the brain tissue thereafter. Proin-
ﬂammatory cytokines as tumour necrosis factor(TNF)-a and
interleukin(IL)-6 activate the expression of MMP-9. MMP-9 is
next involved into further activation of IL-1b and chemokine
CXCL-8 [10].
Extracellularly, the activity of MMPs is regulated by
proteolytic activation of pro-form and the presence of natural
inhibitors of MMPs – tissue inhibitors of MMPs (TIMPs). Among
four known TIMPs, TIMP-1 has the highest afﬁnity to MMP-9.
Different studies applied MMP-9/TIMP-1 ratio as an indicator
of MMP-9 activity in vivo [11,12].
The proteolytic activation of MMP-9 is conducted by active
forms of other metaloproteinases as MMP-2 (gelatinase A) or
MMP-3. Under in vivo conditions MMP-2 is activated on the
cells' surface by complex composed of membrane-type
metalloproteinase (MMP-14) with tissue inhibitor of MMP–
TIMP-2 [13]. However, MMP-3 can be activated by other
proteases including plasmin [14]. Therefore, MMP-3 can beTable 1 – The characteristic of study group. The values of age, N
1st–3rd quartiles [square brackets].
rtP
Age in years (median) 71.0
Sex (female/male) 6/8 
Hypertension (yes/no) 12/2
Type II diabetes (yes/no) 2/12
CHD (yes/no) 8/6 
Atrial ﬁbrillation (yes/no) 2/12
Smoking (yes/no) 8/6 
OCSP classiﬁcation TACI
PACI
LACI
POCI
1
9
3
2
Secondary bleeding (n) 1 
NIHSS at admission (median) 13 [5
NIHSS at discharge (median) 1 [1–
Improvement ratio (median) 4 [2.
CHD, coronary heart disease; OCSP, Oxford Community Stroke Project
anterior circulation infarct; LACI, lacunar infarct; POCI, posterior circulatconsidered as a link between plasmin (activated by rtPA) and
MMP-9. Finally the activation of MMP-9 facilitates the BBB
destruction and secondary bleeding within the ischaemic
focus [6].
Our objective was to ﬁnd the relationship between rtPA
treatment of acute ischaemic stroke and MMP-9 activity, MMP-
3, TIMP-1 serum level related to patients' neurological status.
2. Materials and methods
2.1. Patients
Thirty-ﬁve patients with acute ischaemic stroke conﬁrmed
with computed tomography (CT) scan imaging performed at
the admission were enrolled. The main inclusion criterion was
the admission into the hospital before the 10th hour from the
onset of appearance of focal neurological symptoms (the
stroke onset). Fourteen patients met the criteria for thrombo-
lytic treatment with rtPA (Actilyse, Boehringer Ingelheim). The
rtPA was administrated according to standard protocol
(0.9 mg/kg of body weight, 10% of drug was administrated in
bolus, remaining part was administrated through 1 h in iv.
drip). After enrollment of thrombolytic patients, twenty-one IS
patients who did not met the criteria for rtPA administration
were included into the study as a control group. For non-rtPA
group thrombolytic therapy was not applied due to (1)
extended time between stroke onset and admission to
emergency department or (2) the presence of focal neurologi-
cal symptoms during awakening in the morning (the onset of
IS at night during sleeping, the exact start-hour unknown).
Written informed consent was obtained from each patient (or
from family members when necessary). The local Ethics
Committee (Medical University of Lublin) accepted the proto-
col of the study (agreement No. KE-0254/260/2013).
Exclusion criteria were: (1) regression of neurological
symptoms within 24 h from the onset (Transient Ischaemic
Attack, TIA), (2) history or symptoms suggesting other reasonIHSS and improvement ratio were expressed in median and
A, n = 14 Non-rtPA, n = 21 x2
 [67.5–72.5] 80.5 [70.0–80.5]
12/9
p > 0.1
 18/3
 5/16
12/9
 9/12
10/11
3
12
4
2
1
.5–16] 12.5 [7–20]
12.5] 6 [4–16.25]
5–10] 3 [0.5–6]
 classiﬁcation; TACI, total anterior circulation infarct; PACI, partial
ion infarct.
Fig. 1 – Representative zymograms of sera obtained from
thrombolytic and non-thrombolytic patients. 72 kDa band
corresponds to pro-MMP-2, 92 kDa to pro-MMP-9, 130 kDa
to MMP-9/NGAL heterodimer (description in text), and
200 kDa to MMP-9/MMP-9 homodimer.
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was given in Table 1.
2.2. NIHSS
The neurological status was evaluated at the admission and
discharge with use of National Institutes of Health Stroke Scale
(NIHSS). The neurological status Improvement Ratio (IR) was
calculated as a difference between NIHSS score at the
admission and discharge of patient.
2.3. Sample collection
For thrombolytic patients the venous blood was obtained at
three time-points; time-point 0 – at the admission (1st–4th hour
of stroke); time-point 1 – immediately after rtPA administration
(4th–5th hour of stroke); time-point 2 – on day 5–7 from stroke
onset. Remaining stroke patients had venous blood collection at
two time-points: time-point 1 – at the admission to hospital
(5th–10th hour of stroke) and time-point 2 – on day 5–7 of stroke.
Time-point 0 (1st–4th hour of stroke) was established only for
rtPA patients cause the non-thrombolytic patients were
enrolled after the time designed to time-point 0.
2.4. Zymography
MMP-2 and MMP-9 activities were determined by gelatin
zymography [15]. Brieﬂy, the serum samples after incubation
were diluted 1/50 with redistilled water. 9 ml of diluted serum
was mixed with +3 mL sample buffer with 10% sodium dodecyl
sulfate (SDS). Next, the proteins were separated by electropho-
resis on a 10% polyacrylamide gel with 0.05% gelatin type A from
porcine skin (G2500) (Sigma–Aldrich, St. Louis, MO, USA). Gels
were washed for 1 h with 50 mM Tris–HCl buffer, pH 7.2,
containing 10 mM CaCl2, 0.02% NaN3 and 2.5% Triton X-100.
Incubation was performed for 20 h at 37 8C in the same buffer,
instead using 1% Triton X-100. Gels were stained with 0.1%
Coomassie Blue R-250 in 20% methanol and 10% acetic acid, and
destained in 20% methanol and 10% acetic acid. MMP-2 and
MMP-9 activities were detected as clear bands on a blue
background. Gelatin zymography usually shows the activity
of all gelatinase forms. Inactive pro-forms undergo non-
proteolytic activation during incubation with sample buffer
containing SDS. Enzymes were identiﬁed by comparing their
localization with molecular mass standards (SM0441) (Fermen-
tas Life Sciences, St. Leon-Rot, Germany), as well as with
standards of both gelatinases (911-MP, 902-MP) (R&D Systems,
Minnesota, MN, USA). Zymograms were captured by gel
visualization system (Syngene, Cambridge, UK) and quantiﬁed
with genetools software (Syngene, Cambridge, UK). The activi-
ties of gelatinases were expressed as the optical density (OD) of
the substrate lysis zone.
2.5. ELISA
Commercially available ELISA kits were applied for analysis of
MMP-3 and TIMP-1 serum levels (R&D Systems Inc., USA)
according to manufacturer instructions. Brieﬂy, for MMP-3
evaluation serum samples were diluted 10-times, for
TIMP-1 - 100 times with diluent included to the kits. Theplates were read by Microplate reader (Epoch, Biotek Instru-
ments, USA) at wave length 450 nm corrected at 540 nm.
MMP-9/TIMP-1 ratio, estimated on the basis of zymography
and ELISA results, was expressed in OD/ng/ml.
2.6. Statistical methods
The presence of Gaussian distribution was estimated with
Lillefors test. In case of Gaussian distribution the repeated
measures analysis of variance (ANOVA) with Tukey–Kramer
multiple comparisons post hoc test or t-test were used for
statistical analysis. Otherwise Friedman test with Dunn post
hoc test or Mann–Whitney test were applied. For paired or
repeated measurements the paired t-test or Wilcoxon test as
well as repeated ANOVA or Friedman test was used. Correlation
between NIHSS improvement ratio and biochemical parameters
were evaluated with Spearman correlation. x2 test was applied
for estimation of difference of selected parameters expressed in
Table 1. A p-value < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Zymography
Gelatinolytic activity was detected at 72 kDa molecular weight
(corresponding to pro-MMP-2), 92 kDa (corresponding to pro-
MMP-9), 130 kDa (corresponding to MMP-9/NGAL, heterodimer
with neutrophil gelatinase-B associated lipocalin) and 200 kDa
(corresponding to MMP-9/MMP-9 homodimer) in all analyzed
samples. The activities derived from all forms of MMP-9 (92 kDa,
130 kDa and 200 kDa forms) were summed and the result was
treated as total MMP-9 activity during further calculations. The
active forms of gelatinases were not detected in analyzed
samples. Representative zymogram was shown in Fig. 1.
3.2. MMP-9, TIMP-1, MMP-9/TIMP-1 ratio
The activity of MMP-9 was signiﬁcantly increased during the
rtPA administration in comparison to time-point 0 ( p < 0.05,
Fig. 2 – Total MMP-9 activity in serum of thrombolytic and
non-thrombolytic patients during acute phase of ischaemic
stroke. The increase of MMP-9 activity during thrombolysis
(time-point 1) in comparison to the baseline (time-point 0,
Tukey–Kramer post hoc test, *p < 0.05) and corresponding
time-point of non-thrombolytic group (t-test, yp < 0.05) was
noticed.
Fig. 4 – MMP-3 serum level in thrombolytic and non-
thrombolytic patients during acute phase of ischaemic
stroke. The decrease of MMP-3 level during thrombolysis
(time-point 1) in comparison to time-point 0 (Tukey–
Kramer post hoc test, ***p < 0.001) was noticed.
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corresponding time-point 1 at non-thrombolytic group
( p < 0.05, t-test) (Fig. 2).
Analysis of variance revealed the difference between TIMP-
1 serum levels evaluated in rtPA group ( p = 0.03, repeated
ANOVA). However, the increased TIMP-1 serum level at time-
point 2 did not reach statistical signiﬁcance in post hoc Dunn's
test ( p > 0.05).
The MMP-9/TIMP-1 ratio was insigniﬁcantly elevated
during rtPA administration in comparison to time-point 0
( p = 0.07, repeated ANOVA). The differences between corre-
sponding time-points evaluated in thrombolytic and non-
thrombolytic groups were also statistically insigniﬁcant
( p = 0.08 for time-point 1 and 2, t-test) (Fig. 3).
3.3. MMP-3
MMP-3 serum level signiﬁcantly decreased during rtPA
administration and it is restored on 5 day after stroke onset
( p = 0.0006, repeated ANOVA). The MMP-3 serum level in rtPA
at time-point 1 was insigniﬁcantly higher in comparison withFig. 3 – MMP-9/TIMP-1 ratio in serum of thrombolytic and
non-thrombolytic patients during acute phase of ischaemic
stroke. The increase of MMP-9/TIMP-1 ratio at time-point 1
of thrombolytic group did not reach the statistical
significance.corresponding time-point in non-rtPA group ( p = 0.08, Mann–
Whitney test) (Fig. 4). All results were given in Table 2.
3.4. NIHSS improvement ratio
Among analyzed relationships between biochemical param-
eters (MMP-9 activity, MMP-3, TIMP-1, MMP-9/TIMP-1 serum
level) vs. neurological status improvement ratio only the
correlation with mean value of MMP-3 revealed the negative
relationship. However, the result was located on the border of
statistical signiﬁcance (r = 0.53, p = 0.06, Spearman correla-
tion). The values of remaining correlation coefﬁcients were
statistically insigniﬁcant ( p > 0.1, Spearman correlation).
4. Discussion
According to the literature both gelatinases have the ability to
destruct the basal membrane of endothelium as well as they
digest the proteins located at the tight junctions – occludin and
claudin [8]. Despite the similar structures and substrates of
MMP-2 and MMP-9 only the expression of MMP-9 is induced by
proinﬂammatory cytokines that are elevated in the blood after
acute ischaemia. Therefore, MMP-9 serum activity gradually
increases in the course of the ﬁrst hours and days of IS [16].
Moreover, this enzyme was previously indicated as a risk factor
for intracranial bleeding and poorest clinical outcome after IS
[17]. Animal and clinical observations revealed that high activity
of MMP-9 in the blood of patients treated with rtPA is the risk
factor for developing of intracranial bleeding within ischaemic
focus [18]. Animal studies indicated that the active form of MMP-
9 (86 kDa) can appear in sera of patients treated with rtPA
suggesting the intense activation of MMP-9 trigged by plasmin-
ogen activator [5,6]. During current study the blood was
collected immediately after rtPA administration, however the
active form MMP-9 was not observed. Active MMP-9 is formed by
cleavage of propeptide covering the active site within the
catalytic domain of pro-MMP-9. Under in vivo conditions pro-
MMP-9 is activated by active MMP-2 and MMP-3 [19]. We did not
ﬁnd the active form of MMP-2 in zymography analysis. In
addition, we observed the decrease of MMP-3 serum level
Table 2 – The results of MMP-9 serum activity and MMP-3, TIMP-1, MMP-9/TIMP-1 serum levels at rtPA and non-rtPA
groups during acute phase of ischaemic stroke. The mean values (with SD) or medians (with 1st and 3rd quartiles).
rtPA patients
Time-point 0 Time-point 1 Time-point 2 Repeated ANOVA or
Friedman test
MMP-9 11,380  4750 15,745  6627*,y 14,373  6899 p = 0.01
TIMP-1 213.04 (176.5–233.9) 209.4 (180.5–227.9) 249.05 (221.5–284.2) p = 0.03
MMP-9/TIMP-1 52.54  19.7 73.82  25.4 58.89  26.4 p = 0.07
MMP-3 14.9 (10.3–21.3) 11.1 (9.18–17.7)*** 15.8 (8.24–21.95) p = 0.004
non-rtPA patients
NA Time-point 1 Time-point 2 Paired t-test or
Wilcoxon test
MMP-9 10,439  1032 11,052  4058 p = 0.7
TIMP-1 194.1 (168.6–262.4) 234.71 (183.7–282.8) p = 0.3
MMP-9/TIMP-1 57.14  23.64 53.93  26.23 p = 0.2
MMP-3 17.7 (11.2–26.0) 15.7 (11.8–25.4) p > 0.9
* p < 0.05 the difference in comparison to time-point 0 at rtPA group (Tukey–Kramer).
***p < 0.001 the difference in comparison to time-point 0 at rtPA group (Tukey–Kramer).
yp < 0.05 the difference in comparison to corresponding time-point in non-rtPA group (t-test).
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the thrombolysis is confusing cause the previous report
revealed the increase the MMP-3 level in the course of IS [20].
Our observation did not ﬁnd any ﬂuctuation of MMP-3 serum
level in non-thrombolytic patients during the acute phase of IS.
The absence of active forms of MMP-2 and MMP-9 as well as
the decrease of MMP-3 level after thrombolysis does not
support the previous observations that the appearance of
active MMP-9 in the plasma during thrombolysis is conducted
by MMP-3 [19]. Theoretically, the absence of an active form of
MMP-9 can be explanted by immobilization of the enzyme near
the place of activation, within basal lamina of brain vessels.
Different immunohistochemistry studies showed the intense
MMP-9 activity in the vessel walls [21]. First, the rtPA activates
plasminogen bounded to the clot, next plasmin activates
MMP-3 and MMP-3 activates MMP-9 thereafter. After the
recanalization an active MMP-9 attacks and stays attached to
its substrate (type-IV collagen) within vessel wall. Further
investigations performed on animal models should explain
whether an active form of MMP-9 is attached to the basal
membranes of brain vessels.
Interesting observation is the elevation of total MMP-9
activity after thrombolysis in comparison to non-thrombolytic
patients. Our previous in vitro studies also revealed the
increase of MMP-9 activity without the presence of an active
form (86 kDa) after incubation of serum with different
concentrations of rtPA [22]. The potential source of MMP-9
in vivo can be either the cells derived from clot destructed by
plasmin or the breakdown of MMP-9/MMP-9 homodimer
(200 kDa form) into the 92 kDa form.
Our study showed that MMP-9/TIMP-1 ratio has the trend to
be higher after the thrombolysis in comparison with non-
thrombolytic patients. The higher activity of 92 kDa form after
the thrombolysis supplies the direct precursor of an active
MMP-9 and leads ﬁnally to BBB destruction.
Last ﬁnding was the trend towards the negative correlation
between mean of MMP-3 serum level and NIHSS improvement
ratio of stroke patients. The role of MMP-3 in the pathogenesis
of acute ischaemic stroke is less known in comparison toMMP-9. The PubMed database contains only 28 articles related
to phrase ‘‘ischaemic stroke MMP-3’’ (‘‘ischaemic stroke MMP-
9’’ contains over 400 articles). Previously was noticed the
increase of MMP-3 serum level after IS and its contribution to
pro-MMP-9 activation [14,20,23]. In addition, it was noticed the
elevated expression of MMP-3 within the ischaemic focus [24]
and its involvement into the intracranial bleeding after animal
model of thrombolysis [25]. Our study suggests the possible
relationship between high MMP-3 serum level and the worse
recovery during acute phase of ischaemic stroke.
5. Limitations of the study
Current study has some limitations. First, the results should
be conﬁrmed on larger study group. Second, the ﬁrst blood
collection at non-thrombolytic patients was after the 5th
hour from stroke onset. Because it was impossible to obtain
the blood earlier than 5th hour of stroke (the patients
admitted earlier were enrolled to thrombolytic group
according to the qualifying criteria), the activity or concen-
trations of estimated biochemical parameters within the ﬁrst
5 h is unknown.
6. Conclusions
Thrombolytic therapy with rtPA increases the MMP-9 activity
and decreases the MMP-3 concentration in patients' sera
during acute ischaemic stroke.
RtPA does not contribute to the appearance of active form
of MMP-9 in the bloodstream.
MMP-3 serum level probably is related with worse recovery
of patients during acute phase of ischaemic stroke.
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